Shionogi Inc v. Sandoz Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shionogi Inc. (Delaware/New Jersey)
  • Defendant: Sandoz Inc. (Delaware/New Jersey)
  • Plaintiff's Counsel: FBT GIBBONS LLP
• Case Identification: 2:26-cv-08842, D.N.J., 07/16/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Sandoz has a principal place of business in the district and has allegedly committed acts of infringement there.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's RADICAVA ORS® (edaravone) product infringes a patent covering an oral suspension formulation of the drug.
• Technical Context: The technology involves pharmaceutical formulations for treating Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease for which few treatments are available.
• Key Procedural History: This is a Hatch-Waxman action initiated in response to Sandoz's filing of ANDA No. 220086 and a corresponding Paragraph IV certification notice, which asserts that the patent-in-suit is invalid, unenforceable, or will not be infringed by Sandoz's proposed generic product. The complaint notes that RADICAVA ORS® has been granted Orphan Drug Exclusivity by the FDA. Shionogi acquired the rights to the drug and its associated patents from Tanabe Pharma Corporation effective April 1, 2026. The complaint also lists numerous other pending patent infringement actions in the same district involving RADICAVA ORS®.

Case Timeline

Date	Event
2018-11-02	'586 Patent Priority Date
2022-05-12	FDA Approval of RADICAVA ORS® (NDA 215446)
2024-03-28	FDA Grants Orphan Drug Exclusivity for RADICAVA ORS®
2026-04-01	Shionogi acquires RADICAVA ORS® assets
2026-04-14	'586 Patent Issue Date
2026-06-01	Sandoz sends Paragraph IV Notice Letter to Shionogi
2026-07-16	Complaint Filing Date
2029-05-12	Orphan Drug Exclusivity for RADICAVA ORS® expires

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,599,586 - "Edaravone suspension for oral administration"

• Patent Identification: U.S. Patent No. 12,599,586, "Edaravone suspension for oral administration," issued April 14, 2026.

The Invention Explained

• Problem Addressed: The patent addresses the challenges of administering edaravone, a treatment for ALS Compl. ¶6 The previously available intravenous (IV) formulation is burdensome for patients and caregivers Compl. ¶11 However, developing a suitable oral version is difficult; edaravone has low water solubility, meaning a simple oral solution would require an impractically large volume, while bioavailability from prior suspension attempts was poor Patent, col. 25:1-11
• The Patented Solution: The patent discloses a specific oral suspension formulation that uses a dispersant to keep solid edaravone particles uniformly suspended in water Patent, abstract By controlling the particle size and dissolution characteristics of the edaravone, the invention achieves bioavailability comparable to that of an IV injection but in a small, orally administered volume, thereby reducing the burden on ALS patients Patent, col. 2:10-15 Patent, col. 8:36-49
• Technical Importance: This technology provided the basis for the first oral suspension of edaravone, representing a "major contribution to patient care" by offering a clinically superior and more convenient administration route compared to the prior IV-only option Compl. ¶12

Key Claims at a Glance

• The complaint asserts at least independent claim 1 of the '586 patent Compl. ¶38
• The essential elements of independent claim 1 are:
  • An edaravone suspension for human oral administration comprising water, dispersed edaravone particles, and a dispersant that maintains the edaravone in a solid particle state.
  • The suspension is prepared by a process that includes mixing edaravone particles of a specified size range (a D50 particle size of 10-50 µm and a D90 particle size of 50-200 µm) with the water and dispersant.
  • The edaravone particles have a specified dissolution rate ("80% of more 30 minutes") when tested according to "Dissolution Test Method 2 of Japanese Pharmacopoeia."
• The complaint alleges infringement of one or more claims, suggesting the right to assert additional claims, including dependent claims, is reserved Compl. ¶38

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Sandoz's proposed generic edaravone oral suspension, for which it seeks FDA approval through ANDA No. 220086 Compl. ¶18 Compl. ¶33

Functionality and Market Context

• Sandoz's product is a proposed generic copy of Shionogi's RADICAVA ORS®, which is an oral suspension containing the active pharmaceutical ingredient edaravone at a dose concentration of 105 mg/5 mL Compl. ¶31 Compl. ¶33
• As a generic drug submitted under an ANDA, the Sandoz product is required to be bioequivalent to the reference listed drug, RADICAVA ORS®, and relies on the safety and efficacy data from Shionogi's New Drug Application (NDA) for approval Compl. ¶30 Compl. ¶32 The complaint alleges that Sandoz will market its product for the same indication, the treatment of ALS Compl. ¶8

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that Sandoz's submission of its ANDA constitutes an act of infringement of at least claim 1 of the '586 patent Compl. ¶¶38-39 The complaint does not contain a detailed element-by-element infringement analysis. The infringement theory, inferred from the nature of an ANDA case, is that for Sandoz's product to be a bioequivalent generic copy of RADICAVA ORS®, it must necessarily practice the elements of the asserted claims.

'586 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An edaravone suspension for human oral administration, comprising: water; edaravone particles comprising edaravone and dispersed in the water; and a dispersant...maintains the edaravone particles in a solid particle state...	Sandoz's product is alleged to be an oral "edaravone suspension" and a generic copy of RADICAVA ORS®, which is itself a suspension containing edaravone, water, and excipients.	¶31; ¶33	col. 26:56-65
wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 µm to 50 µm and a D90 particle size in a range of 50 µm to 200 µm...	To achieve bioequivalence with RADICAVA ORS®, the complaint's theory appears to be that the Sandoz product must be made with edaravone particles falling within the claimed size ranges, as these parameters are taught by the patent to be critical for bioavailability.	¶30; ¶38	col. 26:66-27:2
and the edaravone particles have a dissolution rate of 80% of more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.	The complaint's infringement theory suggests that to be a bioequivalent generic, the Sandoz product's active ingredient must exhibit the claimed dissolution profile, which the patent links to achieving the desired therapeutic effect.	¶30; ¶38	col. 27:3-6

• Identified Points of Contention:
  • Scope Questions: A central point of contention may be the "prepared by a process" limitation in claim 1. This is a product-by-process claim element. Under Federal Circuit precedent, process terms in such claims are treated as limitations on the scope of the claim. The case may therefore turn on whether Sandoz's manufacturing process, as detailed in its confidential ANDA, is the same as the process recited in the claim, raising the question: can infringement be avoided if Sandoz uses a different manufacturing process that results in a bioequivalent, or even identical, final product?
  • Technical Questions: A key factual dispute will likely be whether the edaravone particles in Sandoz's proposed product actually meet the D50 and D90 particle size limitations and the specific dissolution rate defined by the Japanese Pharmacopoeia standard. Resolving this will require discovery into the confidential technical details of Sandoz's ANDA filing.

V. Key Claim Terms for Construction

• The Term: "prepared by a process comprising mixing the edaravone particles having a D50 particle size..."

• Context and Importance: This product-by-process language is at the heart of the infringement analysis. Its construction will determine whether infringement requires proof only about the final product's characteristics or also about the specific steps Sandoz uses to manufacture it. Practitioners may focus on this term because if it is construed as a strict process limitation, Sandoz could potentially design a non-infringing process even if its final drug product is identical to Shionogi's.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party could argue that the claim's focus is on the final product's properties, which are achieved by using particles of a certain size at some point in the process. The specification repeatedly emphasizes the bioavailability and final suspension properties as the core of the invention Patent, col. 8:36-49 Patent, col. 26:15-30
  • Evidence for a Narrower Interpretation: The plain language "prepared by a process comprising mixing the edaravone particles having a D50 particle size..." suggests the particles must already possess the specified size characteristics at the time of mixing Patent, col. 26:66-27:2 A party could argue this language mandates a specific sequence of manufacturing steps and excludes processes where particles might be sized in situ or after an initial mixing step.

• The Term: "dispersant"

• Context and Importance: This is a required component of the formulation. The breadth of its definition will determine which suspending agents fall within the claim scope and whether the agent used in Sandoz's formulation qualifies.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification defines a dispersant functionally as "any dispersant that allows the edaravone particles to be well dispersed in water" and provides a non-exhaustive list of examples, including polyvinyl alcohol, methylcellulose, and polysorbate Patent, col. 4:11-14 Patent, col. 4:45-47 This supports a broad definition covering any agent that performs the stated function.
  • Evidence for a Narrower Interpretation: The specification also describes dispersants using quantitative metrics, such as exhibiting a "transmission scattering light intensity of 1% or more" or a "contact angle of 80 degrees or less" Patent, col. 4:17-19 Patent, col. 4:48-49 A party could argue these properties are not merely exemplary but are defining characteristics required of any "dispersant" under the patent, potentially narrowing the term's scope to agents meeting these specific physical criteria.

VI. Other Allegations

• Indirect Infringement: The complaint makes a conclusory allegation that Sandoz will induce or contribute to infringement upon commercialization of its proposed product Compl. ¶44 In the context of an ANDA filing for a product claim, this anticipates that Sandoz's marketing, sale, and distribution activities will cause direct infringement by others (e.g., distributors, pharmacies) in the United States.
• Willful Infringement: The complaint alleges that Sandoz was aware of the '586 patent yet proceeded with its ANDA submission despite an "objectively high likelihood" of infringement Compl. ¶42 This allegation is based on Sandoz's alleged pre-suit knowledge of the patent and forms the basis for a request for enhanced damages.

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of process limitation: will infringement of claim 1 require Shionogi to prove that Sandoz's confidential manufacturing process is materially the same as the "mixing" process recited in the claim, or can infringement be established based on the characteristics of the final product alone? The resolution will define the battleground for infringement.
• A key evidentiary question will be one of technical compliance: does Sandoz's proposed generic product, as described in its ANDA, actually contain edaravone particles that meet the specific D50/D90 size and Japanese Pharmacopoeia dissolution rate limitations recited in claim 1? This factual question will be central to the dispute and its outcome will likely depend on expert analysis of confidential ANDA data obtained during discovery.